Objective: Chemotherapy is a major therapeutic method for bladder urothelial carcinoma (BUC), which can effectively improve the prognosis of BUC patients, but the chemoresistance often leads to chemotherapy failure. This study will research the regulatory roles and molecular mechanism of miR-101-3p in BUC chemoresistance.
Introduction
Bladder cancer is the most common malignant cancer in genitourinary system, bladder urothelial carcinoma (BUC) is the most common classification of bladder cancer, which was called bladder transitional cell carcinoma (BTCC) previously [1] . Chemotherapy is a major therapeutic method for BUC, including systemic and intravesical chemotherapy, which can effectively inhibit the progression of BUC and improve the prognosis of patients [2] . The resistance of cancer cells to chemotherapeutic drugs often leads to chemotherapy failure [3] . Therefore, it is urgent to clarify the mechanism of chemotherapy resistance, especially in BUC.
MicroRNAs are a class of small non-coding RNA molecules, that function in RNA silencing and post-transcriptional regulation of gene expression. MicroRNAs take part in multiform cellular and metabolic pathways, and are involved in the genesis
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International Publisher of a variety of complex diseases, including cancers [4] [5] [6] . Recent literatures reported miR-101-3p was low-expressed and acted as a tumor-suppressing gene in diverse malignant cancers, including bladder cancer [7] [8] [9] [10] . MiR-101-3p inhibited the invasion and migration of bladder cancer 253J-BV cells [11] . Whether miR-101-3p is involved in chemoresistance of BUC and the underlying mechanism is still unknown.
Through bioinformatics analysis, the Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2) gene might be a target gene of miR-101-3p. EZH2 gene is a member of the Polycomb-group (PcG) family, is a core subunit of the polycomb repressor complex 2 (PRC2), participates in the formation of multimeric protein complexes to maintain the transcriptional repressive state of genes over successive cell generations [12] . EZH2 has abnormal expression in almost all malignant cancers [13] [14] [15] [16] .
Materials and Methods

Clinical specimens
89 cases of BUC patients were treated in Shengjing Hospital between May 2012 and Jun 2013. All BUC tissue specimens were obtained through cystoscopy for pathologist diagnosis, the patients' clinicopathological data was complete and clear. Remaining BUC specimens were stored at -80°C with RNAlater Stabilization Solution (Thermo Fisher Scientific, USA) and used to detect the expression of miR-101-3p and EZH2. All patients were diagnosed as BUC for the first time, and were not treated with radiotherapy or chemotherapy before diagnosis.
After diagnosis, all BUC patients received three courses of neoadjuvant chemotherapy with cisplatin (CDDP), each course is 28 days, which consisted of CDDP treatment period (7 days) and interval period (21 days). Then, all BUC patients were examined by cystoscopy and enhanced computerized tomographic scanning (enhanced CT), and the curative effects were evaluated according to RECIST Response Evaluation Criteria. If the patients showed the complete or partial remission, they were classified into the sensitive group (n=37). On the contrary, if the patients' conditions were stable or deteriorating, they were classified into the resistant group (n=52).
Cell culture
Human BUC T24 cell line was achieved from American Type Culture Collection (ATCC), and cultured in Dulbecco's Modified Eagle's medium (DMEM) medium which included 10% fetal bovine serum (Gibco, USA) at the condition of 37℃ and 5% CO2. T24/CDDP cell line has resistance to CDDP and was established previously in our laboratory by inducting with low concentration of CDDP [17] .
Quantitative real time -PCR
Total RNA was extracted from BUC tissues and cells using Trizol reagent. FastKing One Step RT-qPCR Kit (TianGen, China) was applied to examine the expression of miR-101-3p and EZH2 through the 7500 Real-Time PCR System (Applied 
Transfection
The agonist of miR-101-3p (agomiR-101-3p) and its negative control (agomiR-NC) were designed and synthesized by GenePharma Company (China). The expression vector of EZH2 (pUC-EZH2) and its negative control (pUC-NC) were designed and synthesized by Cyagen Company (China). All microRNAs and vectors were transfected with Lipofectamine 3000 (Invitrogen, USA) according to manufacturer's instructions.
Cell proliferation assay
The cells (2×10 4 /well) were seeded in 96-well plate. CCK8 method was used to examine the cell viability according to manufacturer's instructions. 10 μL Cell Counting Kit-8 (Beyotime, China) was added into each well of 96-well plate, and the plate was incubated 2 hours at 37 °C. The SpectraMax M5 microplate reader (Molecular Devices, USA) was applied to detect the value of optical density at 450 nm.
Chemotherapy sensitivity assay
T24 and T24/CDDP Cells were seeded into 96-well plates with 3000 cells per well. 24 hours later, CDDP (10 mg/L, 25 mg/L, 50 mg/L, 75 mg/L, 100 mg/L) was used to treat the cells [17] . The cell viability was examined by CCK8 method after 48 hours. The dose-response curve was charted and the half maximal inhibitory concentration (IC50) was counted according to these data [18] .
Flow cytometry assay
The apoptosis detection was finished with Annexin V-FITC apoptosis detection kit (Biosea, China) through the Flow cytometry according to manufacturer's instructions. The results were analyzed using Diva 8.0 software (Becton Dickinson, USA). Cells in the right lower quadrant were regarded as apoptosis.
Luciferase reporter assay
The target genes of miR-101-3p was predicted by online bioinformatics software TargetScan 7.1. The luciferase reporter vectors (EZH2-M, containing mutant binding site and EZH2-W, containing wild-type binding site) were designed and synthesized by the Genescript company (China). The constructed vectors and microRNAs were cotransfected into HEK 293 cells respectively. The luciferase activity was examined by Dual Luciferase Reporter Gene Assay Kit (Beyotime, China) 48 hours later according to manufacturer's instructions.
Western blotting
Protein was extracted from T24/CDDP cells and determined the concentration with BCA Protein Assay Kit (TianGen, China) according to manufacturer's instructions. Protein samples (20 mg) were handled with SDS-PAGE gels electrophoresis and transferred to PVDF membranes. The PVDF membrane was first hybridized with EZH2 or Multidrug Resistance Associated Protein 1 (MRP1) antibody (4905 and 72202, Cell Signaling Technology, USA), and then hybridized with secondary antibody. Then, the PVDF membrane was incubated with Pro-light HRP Chemiluminescent Kit (TianGen, China), and photographic images were taken. The intensity of the indicated bands was quantified by Image J (National Institutes of Health, USA) and normalized to the reference standard (GAPDH gene).
Statistical analysis
Each experiment was repeated five times, the result data were presented as means ± SD and analyzed with SPSS 23.0 software (IBM, USA). Differences were assessed by one-way analysis of variance (ANOVA) in nonparametric statistics and Student's unpaired t-test. A P<0.05 indicated statistical significance.
Results
The expression of miR-101-3p is positively related to CDDP sensitivity of BUC
The expression of miR-101-3p in resistant group was down-regulated compared with sensitive group (Fig. 1A, P<0.05) . And, the IC50 of T24/CDDP cell line to CDDP was 81.17±7.33 mg/L, T24/CDDP cell line showed much lower sensitivity than T24 cell line which IC50 to CDDP was 26.21±3.14 mg/L (Fig. 1B,  P<0 .05). The expression of miR-101-3p in T24/CDDP cells was much lower than that in T24 cells (Fig. 1C,  P<0 .05). These findings reveal the expression of miR-101-3p is positively related to CDDP sensitivity of BUC, miR-101-3p plays an important role in chemoresistance of BUC to CDDP.
Up-regulation of miR-101-3p advances sensitivity of T24/CDDP cells to CDDP
Transfection with agomiR-101-3p up-regulated the expression of miR-101-3p in T24/CDDP cells. The miR-101-3p enhancement decreased the IC50 of T24/CDDP cells to CDDP from 81.06±7.09 mg/L to 38.72±3.25 mg/L (P<0.05, Fig. 2A) , and inhibited the expression of MRP1 protein in T24/CDDP cells (P<0.05, Fig. 2B ).
Furthermore, in the T24/CDDP cells treating with CDDP (10 mg/L), the miR-101-3p enhancement depressed cell viability (Fig.2C, P<0.05) , and promoted cell apoptosis (Fig. 2D, P<0.05) . 
EZH2 gene is a target gene of miR-101-3p in BUC cells
Through online bioinformatics software TargetScan 7.1, two potential binding sites of miR-101-3p was predicted in the 59-65 bp and 114-121bp of EZH2 3′-UTR (Fig. 3A) . Luciferase reporter assay proved miR-101-3p could specifically combine with wild-type binding site to restrain the luciferase activity (Fig. 3B, P<0.05) . And, miR-101-3p enhancement depressed obviously the expression of EZH2 protein in T24/CDDP cells (Fig. 3C, P<0.05) . Moreover, the EZH2 expression in T24/CDDP cell line and resistant group specimens was much higher than that in T24 cell line and sensitive group specimens respectively (Fig. 3D,E, P<0.05) . And, the EZH2 expression showed an inverse correlation with the expression of miR-101-3p (P<0.01). In addition, the co-expression patterns analysis showed a negative correlation between miR-101-3p and EZH2 in BUC tissues (Fig. 3F) (r=-0.3951, P<0.001) . These results confirmed that miR-101-3p could bind to EZH2 and negatively regulate the expression of EZH2, and EZH2 was a target gene of miR-101-3p.
EZH2 mediates the regulation of miR-101-3p on CDDP sensitivity of T24/CDDP cells
To determine whether EZH2 mediates the regulatory effects of miR-101-3p on chemosensitivity, knockdown of EZH2 by miR-101-3p enhancement was rescued by transfection with pUC-EZH2 prior to the detection of CDDP sensitivity, MRP1 expression and cytotoxicity induced by CDDP.
Compared with agomiR-101-3p + pUC-NC group, the IC50 of agomiR-101-3p + pUC-EZH2 group to CDDP raised significantly (Fig.4A, P<0.05) , and the expression of MRP1 protein increased remarkably (Fig.4B, P<0.05) .
Furthermore, under treating with CDDP (10 mg/L), compared with agomiR-101-3p + pUC-NC group, the cell viability of agomiR-101-3p + pUC-EZH2 group increased (Fig.2C, P<0 .05), and cell apoptosis showed a significant decline (Fig.2D, 
P<0.05).
Discussion
It is well known that microRNAs participate in a variety of important physiological functions by regulating the expression of target genes, their abnormal expression resulted to the genesis of a variety of complex diseases, including cancers. Some recent reports discussed microRNAs take part in formation of chemoresistance of malignant cancers, including BUC [19] [20] [21] [22] .
Our study firstly found miR-101-3p was low-expressed in CDDP resistant BUC patients and cell line, revealed the miR-101-3p expression was positively related to CDDP sensitivity of BUC. CDDP interferes with DNA replication, kills the fastest proliferating tumor cells, and is used widely in chemotherapy of many malignant cancers. Following experiment validated that miR-101-3p enhancement could inhibit the IC50 of T24/CDDP cells to CDDP, and promote the cytotoxicity induced by CDDP, which proved miR-101-3p played an important role in chemoresistance of BUC to CDDP.
Furthermore, the up-regulation of miR-101-3p also depressed the expression of MRP1 protein. MRP1 belonged to the ATP-binding cassette (ABC) transporters superfamily, which participates in the molecule transportation across the cellular membranes, which can pump chemotherapeutic drugs out of cells before they work [23] [24] [25] . Together, miR-101-3p advances CDDP sensitivity through silencing MRP1 expression, but the underlying mechanism is still unknown. In consideration of microRNAs paly their roles through regulating their target genes, such as miR-429 and BMI1 [26] , we predicted EZH2 gene might be a target of miR-101-3p by using online bioinformatics software. And, Hou Y reported miR-101-3p could regulate the proliferation of lung squamous carcinoma via targeting EZH2 [27] . EZH2 is an activator of gene expression, acting through multiple signaling pathways in distinct cancer types. Increasing evidence indicates EZH2 acts as an oncogene and is central to initiation, growth and progression of urological cancers. A series of following gain-of-function experiments, such as luciferase reporter assay and western blotting, proved EZH2 gene was the target gene of miR-101-3p. Lv Y reported knockdown of EZH2 reduced the expression of MRP1 and advanced cisplatin sensitivity in lung adenocarcinoma [28] . To sum up, we speculate miR-101-3p might modulate the CDDP resistance of BUC cells through targeted silencing EZH2.
To verify this hypothesis, knockdown of EZH2 by miR-101-3p enhancement was rescued by transfection with pUC-EZH2. The following experiments found that up-regulation of EZH2 largely reversed the regulatory roles of miR-101-3p on CDDP resistance of T24/CDDP cells. Accordingly, EZH2 mediated the regulation of miR-101-3p on CDDP resistance in T24/CDDP cells.
In summary, the expression of miR-101-3p is positively related to CDDP sensitivity of BUC, miR-101-3p advances sensitivity of BUC on CDDP through targeted silencing EZH2. These founding might provide guidance for the clinical chemotherapy of BUC.
